Perspective Therapeutics (CATX) Competitors

RxSight (NASDAQ:RXST) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.

Does the MarketBeat Community favor RXST or CATX?

RxSight received 16 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 97.30% of users gave Perspective Therapeutics an outperform vote while only 63.41% of users gave RxSight an outperform vote.

Company	Underperform	Outperform
RxSight	Outperform Votes 52 63.41%	Underperform Votes 30 36.59%
Perspective Therapeutics	Outperform Votes 36 97.30%	Underperform Votes 1 2.70%

Do insiders and institutionals hold more shares of RXST or CATX?

78.8% of RxSight shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 9.4% of RxSight shares are owned by company insiders. Comparatively, 3.7% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts rate RXST or CATX?

RxSight presently has a consensus target price of $37.90, indicating a potential upside of 160.37%. Perspective Therapeutics has a consensus target price of $12.63, indicating a potential upside of 270.23%. Given Perspective Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Perspective Therapeutics is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Perspective Therapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.20

Which has preferable earnings & valuation, RXST or CATX?

Perspective Therapeutics has lower revenue, but higher earnings than RxSight.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$148.31M	3.99	-$48.61M	-$0.67	-21.73
Perspective Therapeutics	$1.43M	177.01	-$46.51M	N/A	N/A

Which has more risk and volatility, RXST or CATX?

RxSight has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Is RXST or CATX more profitable?

RxSight has a net margin of -23.92% compared to Perspective Therapeutics' net margin of -4,096.66%. RxSight's return on equity of -14.00% beat Perspective Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-23.92%	-14.00%	-12.51%
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Does the media favor RXST or CATX?

In the previous week, Perspective Therapeutics had 5 more articles in the media than RxSight. MarketBeat recorded 8 mentions for Perspective Therapeutics and 3 mentions for RxSight. RxSight's average media sentiment score of 1.26 beat Perspective Therapeutics' score of 0.90 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perspective Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

RxSight beats Perspective Therapeutics on 9 of the 17 factors compared between the two stocks.